1. Home
  2. BG vs OCEAW Comparison

BG vs OCEAW Comparison

Compare BG & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BG
  • OCEAW
  • Stock Information
  • Founded
  • BG 1818
  • OCEAW N/A
  • Country
  • BG United States
  • OCEAW United States
  • Employees
  • BG N/A
  • OCEAW 7
  • Industry
  • BG Packaged Foods
  • OCEAW Biotechnology: Pharmaceutical Preparations
  • Sector
  • BG Consumer Staples
  • OCEAW Health Care
  • Exchange
  • BG Nasdaq
  • OCEAW Nasdaq
  • Market Cap
  • BG N/A
  • OCEAW N/A
  • IPO Year
  • BG N/A
  • OCEAW 2021
  • Fundamental
  • Price
  • BG $80.91
  • OCEAW $0.02
  • Analyst Decision
  • BG Buy
  • OCEAW
  • Analyst Count
  • BG 4
  • OCEAW 0
  • Target Price
  • BG $80.75
  • OCEAW N/A
  • AVG Volume (30 Days)
  • BG 1.6M
  • OCEAW N/A
  • Earning Date
  • BG 05-07-2025
  • OCEAW N/A
  • Dividend Yield
  • BG 3.37%
  • OCEAW N/A
  • EPS Growth
  • BG N/A
  • OCEAW N/A
  • EPS
  • BG 7.99
  • OCEAW N/A
  • Revenue
  • BG $53,108,000,000.00
  • OCEAW N/A
  • Revenue This Year
  • BG $7.65
  • OCEAW N/A
  • Revenue Next Year
  • BG $1.82
  • OCEAW N/A
  • P/E Ratio
  • BG $10.11
  • OCEAW N/A
  • Revenue Growth
  • BG N/A
  • OCEAW N/A
  • 52 Week Low
  • BG $67.40
  • OCEAW N/A
  • 52 Week High
  • BG $114.92
  • OCEAW N/A
  • Technical
  • Relative Strength Index (RSI)
  • BG 63.99
  • OCEAW N/A
  • Support Level
  • BG $78.76
  • OCEAW N/A
  • Resistance Level
  • BG $79.01
  • OCEAW N/A
  • Average True Range (ATR)
  • BG 2.57
  • OCEAW 0.00
  • MACD
  • BG 0.58
  • OCEAW 0.00
  • Stochastic Oscillator
  • BG 96.71
  • OCEAW 0.00

About OCEAW Ocean Biomediacal Inc.

Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.

Share on Social Networks: